

## Disclosure of Editors' Financial Relationships

*The American Journal of Psychiatry* requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

**Ned H. Kalin, M.D. (Editor-in-Chief):** Dr. Kalin reports serving as a consultant to the Board of Scientific Advisors, Pritzker Neuropsychiatric Disorders Consortium; Skyland Trail National Advisory Board, CME Outfitters, LLC, Corcept Therapeutics Incorporated, and the Institute for Early Adversity Research External Scientific Advisory Board at the University of Texas-Austin.

**Elisabeth Binder, M.D., Ph.D. (Deputy Editor):** Dr. Binder reports no financial relationships with commercial interests.

**Kathleen T. Brady, M.D., Ph.D. (Deputy Editor):** Dr. Brady reports serving as a consultant to Embera Pharma.

**David A. Lewis, M.D. (Deputy Editor):** Dr. Lewis reports currently receiving investigator-initiated research support from Pfizer and Merck.

**Daniel S. Pine, M.D. (Deputy Editor):** Dr. Pine reports no financial relationships with commercial interests.

**Carolyn Rodriguez, M.D., Ph.D. (Deputy Editor):** Dr. Rodriguez reports in the past 3 years having served as a consultant to Epiodyne and receiving grant support from Biohaven Pharmaceuticals.

**Madhukar Trivedi, M.D. (Deputy Editor):** Dr. Trivedi reports serving as a consultant or on advisory boards for Acadia Pharmaceuticals, Inc., Allergan, Inc., Alto Neuroscience Inc, Applied Clinical Intelligence, Axsome Therapeutics, Boehringer Ingelheim, GH Research Limited, GreenLight VitalSign6 Inc, Janssen, Myriad Neuroscience, Navitor Pharmaceutical Inc, Otsuka, Perception Neuroscience, Pharmerit International, SAGE Therapeutics, and Signant Health.